Wall Street brokerages expect SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings of ($2.40) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for SAGE Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.68) and the highest estimate coming in at ($2.02). SAGE Therapeutics posted earnings of ($1.97) per share in the same quarter last year, which indicates a negative year over year growth rate of 21.8%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 1st.

According to Zacks, analysts expect that SAGE Therapeutics will report full year earnings of ($7.37) per share for the current financial year, with EPS estimates ranging from ($9.21) to ($5.24). For the next financial year, analysts forecast that the firm will report earnings of ($10.42) per share, with EPS estimates ranging from ($20.74) to ($5.06). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The company had revenue of $90.00 million during the quarter.

Several brokerages have commented on SAGE. Canaccord Genuity restated a “buy” rating and issued a $220.00 price objective on shares of SAGE Therapeutics in a report on Tuesday, June 12th. Cowen restated a “buy” rating and issued a $207.00 price objective on shares of SAGE Therapeutics in a report on Thursday, June 14th. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 18th. Morgan Stanley upped their price objective on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a report on Friday, July 13th. Finally, LADENBURG THALM/SH SH began coverage on shares of SAGE Therapeutics in a report on Wednesday, June 6th. They issued a “buy” rating and a $230.00 price objective for the company. Two analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $199.19.

NASDAQ SAGE traded down $3.38 during trading on Monday, hitting $142.63. The company had a trading volume of 349,600 shares, compared to its average volume of 499,493. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97. The firm has a market capitalization of $6.81 billion, a PE ratio of -20.54 and a beta of 2.90.

Several institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of SAGE Therapeutics by 1.6% in the 2nd quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock worth $1,092,169,000 after acquiring an additional 110,687 shares in the last quarter. BlackRock Inc. increased its stake in SAGE Therapeutics by 9.6% during the 1st quarter. BlackRock Inc. now owns 3,774,283 shares of the biopharmaceutical company’s stock valued at $607,923,000 after purchasing an additional 330,112 shares in the last quarter. OppenheimerFunds Inc. increased its stake in SAGE Therapeutics by 2.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock valued at $250,162,000 after purchasing an additional 34,389 shares in the last quarter. Bank of New York Mellon Corp increased its stake in SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock valued at $244,898,000 after purchasing an additional 110,134 shares in the last quarter. Finally, BB Biotech AG increased its stake in SAGE Therapeutics by 6.9% during the 2nd quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock valued at $167,702,000 after purchasing an additional 68,934 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: Asset Allocation Models, Which is Right For You?

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.